Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/18998
Title
Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023
Author(s)
Antunes, Liliana | Mazagatos, Clara ISCIII | Martínez-Baz, Iván | Gomez, Verónica | Borg, Maria-Louise | Petrović, Goranka | Duffy, Róisín | Dufrasne, François E | Dürrwald, Ralf | Lazar, Mihaela | Jancoriene, Ligita | Oroszi, Beatrix | Husa, Petr | Howard, Jennifer | Melo, Aryse | Pozo Sanchez, Francisco ISCIII | Pérez-Gimeno, Gloria | Castilla, Jesús | Machado, Ausenda | Džiugytė, Aušra | Karabuva, Svjetlana | Fitzgerald, Margaret | Fierens, Sébastien | Tolksdorf, Kristin | Popovici, Silvia-Odette | Mickienė, Auksė | Túri, Gergő | Součková, Lenka | Nicolay, Nathalie | Rose, Angela Mc | European Hospital Vaccine Effectiveness Group
Date issued
2024-01
Citation
Euro Surveill. 2024 Jan;29(3):2300708.
Language
Inglés
Document type
research article
Abstract
We conducted a multicentre hospital-based test-negative case-control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14-89 days post-vaccination, 15% (95% CI: -12 to 35) at 90-179 days, and lower to no effect thereafter.
Subject
COVID-19 | COVID-19 bivalent vaccines | Europe | Hospitalisation | SARI | SARS-CoV-2 | Vaccine effectiveness | XBB
MESH
COVID-19 Vaccines | COVID-19 | Humans | Case-Control Studies | SARS-CoV-2 | Hospitalization | Europe | RNA, Messenger
Online version
DOI
Collections